Research Article
Public versus Private Drug Insurance and Outcomes of Patients Requiring Biologic Therapies for Inflammatory Bowel Disease
Table 2
Demographic and clinical characteristics.
| | Characteristic | All patients
() | Type of drug insurance coverage | value | Public
() | Private
() |
| | Age at study inclusion, years. Mean (SD) | 32.5 (12.6) | 31.8 (13.7) | 32.8 (12.1) | 0.548 | | Age at IBD diagnosis, years. Mean (SD) | 24.2 (11.4) | 25.4 (12.9) | 23.7 (10.7) | 0.316 | | Disease duration, years. Median (IQR) | 8.5 (8.8) | 6.9 (6.8) | 9.1 (9.5) | 0.247 | | Male Gender. (%) | 136 (51) | 38 (49) | 98 (51) | 0.772 | | Family history of IBD. (%) | 47 (18) | 13 (17) | 34 (18) | 0.858 | | Smoking status. (%) | | | | | | Never | 215 (80) | 63 (82) | 152 (80) | 0.677 | | Former or Current | 53 (20) | 14 (18) | 39 (20) | | | Neighborhood income quintile. (%) | | | | 0.880 | | (1) | 29 (11) | 9 (12) | 20 (10) | | (2) | 38 (14) | 13 (17) | 25 (13) | | (3) | 57 (22) | 16 (21) | 41 (22) | | (4) | 56 (21) | 17 (22) | 39 (22) | | (5) | 83 (32) | 21 (28) | 62 (28) | | Steroid dependent/refractory. (%) | 148 (55) | 49 (64) | 99 (52) | 0.079 | | Previous/current immunomodulator. n (%) | | | | | | Thiopurines | 147 (55) | 51 (66) | 96 (50) | 0.017 | | Methotrexate | 28 (10) | 9 (12) | 19 (10) | 0.673 | | Any immunomodulator | 157 (59) | 55 (71) | 102 (53) | 0.007 | | IBD type. (%) | | | | | | Crohn’s disease | 165 (62) | 48 (62) | 117 (61) | 0.869 | | Ulcerative colitis | 103 (38) | 29 (38) | 74 (39) | | | Montreal classification, Crohn’s disease. n (%) | | | | 0.115 | | B1 (nonstricturing, nonpenetrating) | 82 (50) | 30 (62) | 52 (45) | | B2 (stricturing) | 52 (32) | 12 (25) | 40 (35) | | B3 (penetrating) | 30 (18) | 6 (13) | 24 (21) | | Extension of Ulcerative colitis. (%) | | | | | | Extensive or Pancolitis | 78 (76) | 22 (76) | 56 (76) | 0.989 | | Distal (left-sided/proctitis) | 25 (24) | 7 (24) | 18 (24) | | | IBD of aggressive behavior. (%) | 168 (63) | 50 (65) | 127 (67) | 0.808 | | Previous surgery. (%) | 60 (22) | 14 (18) | 46 (24) | 0.294 | | Crohn’s disease | 54 (33) | 13 (27) | 41 (35) | 0.322 | | Ulcerative colitis | 6 (6) | 1 (3) | 5 (7) | 0.519 | | Biologic agent initiated. (%) | | | | | | Infliximab | 243 (91) | 70 (91) | 173 (91) | 0.932 | | Adalimumab | 25 (9) | 7 (9) | 18 (9) | | | Inpatient initiation of anti-TNF. (%) | 63 (24) | 24 (31) | 39 (20) | 0.079 | | Compassionate use program. (%) | 40 (15) | 18 (23) | 22 (12) | 0.014 | | Use of co-pay scheme. (%) | 30 (11) | N/A | 30 (16) | N/A |
|
|
